Peptide Encyclopedia / Selank
EncyclopediaSelank is a synthetic heptapeptide based on the immune peptide tuftsin, developed in Russia and sold there as a 0.15% intranasal solution for anxiety. It carries no FDA or EU approval, and in the US it exists only as an unapproved research chemical. Educational only, not medical advice.
| Also known as | Selank, TP-7, Selanc |
| Regulatory status | Selank is NOT FDA-approved and is not approved in the EU or US. |
Selank is NOT FDA-approved and is not approved in the EU or US. It is registered/approved only in Russia (developed at the Institute of Molecular Genetics, Russian Academy of Sciences), where it is marketed as a 0.15% intranasal solution for anxiety/neurasthenic indications. In the US it is available only as an unapproved research chemical.
Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, extended with a C-terminal Pro-Gly-Pro tail to improve metabolic stability. Proposed mechanisms include modulation of enkephalin metabolism (increasing the half-life of leu-enkephalin), effects on monoaminergic and GABAergic neurotransmission, modulation of BDNF and inflammatory cytokine expression, and immunomodulatory (tuftsin-like) activity. Mechanistic detail derives mainly from animal and Russian clinical/biomarker studies. Pharmacokinetics (half-life Very short in plasma; the parent peptide is rapidly degraded (intact peptide reported to persist on the order of minutes), though active metabolites and CNS effects may outlast plasma presence.): Administered intranasally in clinical Russian use. The parent heptapeptide is rapidly hydrolyzed by peptidases; detailed validated human PK parameters are limited and largely confined to Russian-language literature. No robustly verified Western-standard human PK half-life found beyond reports of rapid degradation.
Human evidence is limited and primarily from small Russian trials. A 2008 comparative trial (n=62) reported anxiolytic efficacy in generalized anxiety disorder/neurasthenia comparable to the benzodiazepine medazepam, with additional antiasthenic effects and changes in serum enkephalin activity. Trials are small, mostly open or active-comparator, and not replicated to Western regulatory standards. Honest level: limited-human. Reported use: In Russian clinical practice Selank is reported as a 0.15% intranasal spray. Community/clinic-reported off-label use elsewhere is intranasal (commonly reported in the range of roughly 250-900 mcg/day) for anxiety and cognitive support. Because rigorous dose-finding trials are lacking outside Russia, these figures reflect reported practice rather than validated recommendations.
In the available small Russian trials Selank was generally well tolerated, reportedly without the sedation, dependence, or withdrawal associated with benzodiazepines. However, long-term safety, large-scale adverse-event data, and Western regulatory safety review are lacking. Research-chemical sourcing carries purity and sterility risks. No verified large safety dataset found..
Pregnancy and breastfeeding (no adequate safety data), No formally established clinical contraindications due to limited trial data.
No well-characterized drug interactions documented; potential additive effects with other CNS-active/anxiolytic agents are unstudied
Log every dose and injection site, get the reconstitution and units math automatically, follow your cycle, and record how you feel, then export a provider report. Selank tracker, free to start.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Selank may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
